Researchers advance blood tests’ ability to detect cancer earlier
Pharma Times
JANUARY 23, 2024
The advancement could allow earlier detection of cancer in the blood and better treatment
Tue.Jan 23, 2024
130 
FDA orders new cancer warnings for CAR-T therapies
Bio Pharma Dive
JANUARY 23, 2024
A black box warning for secondary T cell malignancies should be added to the labeling of all six approved CAR-T therapies, the agency said.
Join 21,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
UK MHRA strengthens regulations on fluoroquinolone antibiotics
Pharmaceutical Technology
JANUARY 23, 2024
The UK MHRA has introduced further restrictions on the usage of fluoroquinolone antibiotics, strengthening the previous regulations.
NIPERs should consider ways to fill faculty positions in the absence of suitable applications: DoP study
AuroBlog - Aurous Healthcare Clinical Trials blog
JANUARY 23, 2024
The National Institutes of Pharmaceutical Education and Research (NIPERs) can consider their own in-house scientists for the new faculty positions or recruit pharmaceutical industry professionals for the Professor of Practice positions in the absence of suitable applications for faculty positions, recommends a study by the Department of Pharmaceuticals (DoP).
From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Genentech signs nanoparticle deal worth up to $644m with GenEdit
Pharmaceutical Technology
JANUARY 23, 2024
Genentech will utilise GenEdit’s non-viral polymer nanoparticles for gene therapy delivery in autoimmune diseases.
Your Body Has a Built-in Weight Loss System You May Not Know About
AuroBlog - Aurous Healthcare Clinical Trials blog
JANUARY 23, 2024
Wegovy, Ozempic and Mounjaro are weight loss and diabetes drugs that have made quite a splash in health news. They target regulatory pathways involved in both obesity and diabetes and are widely considered breakthroughs for weight loss and blood sugar control. [link] But do these drugs point toward a root cause of metabolic disease?
Sign up to get articles personalized to your interests!
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
More Trending
January 23, 2024: Ethics Consultation Documents Now Available for RAMP Trial
Rethinking Clinical Trials
JANUARY 23, 2024
Ethics and regulatory onboarding documentation is now available for RAMP, one of the NIH Pragmatic Trials Collaboratory's newest pragmatic clinical trials. The documents include meeting minutes and supplementary materials summarizing recent discussions of ethics and regulatory issues associated with the study. The consultation took place by video conference and included representation from the study's principal investigator and study team, members of the NIH Collaboratory's Ethics and Regulatory
Pharmas back Accent’s plan to make RNA-targeting cancer drugs
Bio Pharma Dive
JANUARY 23, 2024
J&J and Bristol Myers joined the latest funding round for the startup, which was led by the newly launched Mirae Asset Capital Life Science.
Newly launched Calluna raises $81m to advance monoclonal antibody pipeline
Pharmaceutical Technology
JANUARY 23, 2024
Calluna has four monoclonal antibody candidates in the pipeline under development for inflammatory and fibrotic diseases.
Grand Rounds January 19, 2024: Why Are Imaging RCTs Different? Lessons From Chest Pain Evaluation Trials (Pamela S. Douglas, MD, MACC, FASE, FAHA)
Rethinking Clinical Trials
JANUARY 23, 2024
Speaker Pamela S. Douglas, MD, MACC, FASE, FAHA Ursula Geller Professor of Research in Cardiovascular Diseases Duke Clinical Research Institute – Duke University Past President, American College of Cardiology Past President, American Society of Echocardiography Slides Keywords Chest Pain, Cardiovascular Imaging, Coronary Artery Disease Key Points Imaging has transformed cardiology and many other fields.
Cara Therapeutics cuts 50% of staff and drops kidney disease program
Pharmaceutical Technology
JANUARY 23, 2024
The company ceased activity for its CKD program to sharpen its clinical focus in the Phase II/III program for notalgia paresthetica.
MIT researchers repurpose cancer compound to treat PKD
Pharma Times
JANUARY 23, 2024
Autosomal dominant polycystic kidney disease affects more than 12 million people globally
Inhalation Sciences and Actarmo enter respiratory drugs collaboration
Pharmaceutical Technology
JANUARY 23, 2024
Inhalation Sciences has entered into a collaboration with Germany-based Actarmo Medical for respiratory drug development services.
Lilly trumpets early success with deafness gene therapy
pharmaphorum
JANUARY 23, 2024
Eli Lilly’s gene therapy for otoferlin-related deafness has restored the hearing of the first child enrolled in its ongoing phase 1/2 trial
The New Age of Decentralized Clinical Trials
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
Sanofi signs agreement to acquire Inhibrx for $1.7bn
Pharmaceutical Technology
JANUARY 23, 2024
Sanofi has signed a definitive agreement for the acquisition of all outstanding shares of Inhibrx for an equity value of $1.7bn.
Sanofi snaps up Inhibrx and its rare disease drug for $2.2bn
pharmaphorum
JANUARY 23, 2024
Sanofi agrees $2.2bn deal to buy California biotech Inhibrx and its long-acting therapy for rare disease AATD, which causes life-threatening emphysema.
Genmab loses appeal in Darzalex royalties arbitration case against Johnson & Johnson
Fierce Pharma
JANUARY 23, 2024
While sales for Johnson & Johnson’s Darzalex continue to boom—as the company reported in its quarterly earnings presentation on Tuesday—the pharma major got more good news about its blockbuster | An appeal arbitrator has rejected Genmab’s claim that it is due additional milestone and royalty payments from Johnson & Johnson for Darzalex. The Danish biotech was hoping to overturn a 2-1 ruling in a second arbitration between the companies over Darzalex royalties.
Take the hybrid road to bring clinical trials to patients
pharmaphorum
JANUARY 23, 2024
Bringing clinical trials to patients has become easier with the advent of digital technologies and decentralised clinical trials (DCTs). Learn how the hybrid approach combining traditional and digital methods can benefit patients and advance medical research.
J&J, Legend's Carvykti bid for earlier multiple myeloma use will face FDA adcomm
Fierce Pharma
JANUARY 23, 2024
Early evidence showing Carvykti’s potential to prolong patients’ lives in an earlier multiple myeloma setting didn’t save Johnson & Johnson and Legend Biotech’s CAR-T medicine from a public int | Early evidence showing the drug's potential to prolong patients' lives didn't save Johnson & Johnson and Legend Biotech's Carvykti from a public interrogation by the FDA.
Digital marketing firm Viseven gets private equity backing
pharmaphorum
JANUARY 23, 2024
Ukraine-based digital pharma marketing specialist Viseven gets private equity investment from Horizon Capital
Ahead of key Stelara patent cliff, J&J's pharma business churns out growth
Fierce Pharma
JANUARY 23, 2024
Ahead of key Stelara patent cliff, J&J's pharma business churns out growth fkansteiner Tue, 01/23/2024 - 11:32
NICE backs two AIs for stroke diagnosis in NHS
pharmaphorum
JANUARY 23, 2024
Two artificial intelligence-powered software tools – e-Stroke and RapidAI – have been recommended for use in the NHS to help detect stroke from CT brain scans by NICE. The health technology assessment (HTA) agency said there is some evidence that people admitted to hospital with a suspected had faster or better access to treatment after using the software, although for now it is unclear whether that was a direct consequence of the digital technology.
The New Age of Decentralized Clinical Trials
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
Johnson & Johnson inks $700M deal to resolve talc consumer protection claims from 42 states
Fierce Pharma
JANUARY 23, 2024
After failing to resolve a mountain of talcum-powder lawsuits through two unsuccessful bankruptcy attempts, Johnson & Johnson has agreed to a $700 million settlement that would free the company | After failing to resolve a mountain of talcum-powder lawsuits through two unsuccessful bankruptcy attempts, Johnson & Johnson has agreed to a $700 million settlement that would free the company from some consumer protection claims—and a small part of the talc litigation that it faces.
Using Blockchain to Minimize Consumers’ Risk Aversion Toward Generic Drugs
Pharmaceutical Commerce
JANUARY 23, 2024
Study describes how a game theoretic model can successfully analyze how adoption of blockchain technology can reveal quality information.
Trial raises hopes for simple Alzheimer’s blood test
pharmaphorum
JANUARY 23, 2024
Study finds evidence that an AlZpath immunoassay for phosphorylated tau could deliver an effective blood test for Alzheimer's, paving the way for screening and early treatment
Pharma manufacturer Gerresheimer gives Georgia an $88 million injection of funds
Outsourcing Pharma
JANUARY 23, 2024
Manufacturer for the pharma and life sciences industry, Gerresheimer, is investing more than $88 million to expand its operations in Peachtree City, Georgia.
Unlocking Excellence: How Catalent Is Transforming Japan’s Clinical Research
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
Fixing the inequity of drug access outside of the US
pharmaphorum
JANUARY 23, 2024
In this new episode of the pharmaphorum podcast, web editor Nicole Raleigh welcomes guest Cem Zorluhar, CEO of Er-Kim Pharmaceuticals, for a conversation on antimicrobial resistance (AMR) and what the biotech industry should be focussing on in order to address this critical issue outside of the West.
Sano Genetics raises a further $11.4 million for its 'precision medicine revolution'
Outsourcing Pharma
JANUARY 23, 2024
Sano Genetics says it is developing software that will enable âthe precision medicine revolutionâ and has raised $11.4 million in new funding.
Which pharmaceutical drugs have the most patents?
Drug Patent Watch
JANUARY 23, 2024
This chart shows the pharmaceutical drugs with the greatest number of patents still in force. The number of patents covering a drug can be indicative of the value of a… The post Which pharmaceutical drugs have the most patents? appeared first on DrugPatentWatch - Make Better Decisions.
Saama embeds new features within its AI platform to speed up treatments reaching patients
Outsourcing Pharma
JANUARY 23, 2024
Yesterday (January 22), Saama announced the release of several âgroundbreakingâ features within its AI-driven platform, including generative AI (GenAI) chat and interactive review listings (IRL), that it says create a workflow-driven environment for cross-functional collaboration.
How Machine Learning Drives Clinical Trial Efficiency
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Let's personalize your content